2002
Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high‐risk prostate cancer
D'Amico A, Saegaert T, Chen M, Renshaw A, George D, Oh W, Kantoff P. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high‐risk prostate cancer. Cancer 2002, 95: 275-280. PMID: 12124826, DOI: 10.1002/cncr.10673.Peer-Reviewed Original ResearchConceptsAndrogen suppression therapyProstate specific antigen failureProstate specific antigenProstate cancer patientsHigh-risk prostate cancer patientsMonths of androgen suppression therapyNeoadjuvant androgen suppression therapyRadiation therapyHgb levelsCancer patientsPSA failureHormone therapyRelative risk of PSA failureTreatment of prostate cancer patientsEstimates of PSA outcomeHigh-risk prostate cancerMultivariate analysisRisk of PSA failureExternal beam radiation therapyThree-dimensional conformal RTCox regression multivariate analysisBaseline PSA levelsEarly PSA failureNeoadjuvant hormonal therapyBeam radiation therapyWhat is “biochemical failure” in prostate cancer?
Lagu T, Wells C, Penson D, Concato J. What is “biochemical failure” in prostate cancer? Journal Of Clinical Epidemiology 2002, 55: 631. DOI: 10.1016/s0895-4356(02)00425-0.Peer-Reviewed Original ResearchProstate-specific antigenPSA failureMedian timeType of treatmentPSA slopeProstate cancerPost-treatment prostate-specific antigenVeterans Affairs Healthcare SystemAge-matched menProportion of menBiochemical failureSurgical failureTreatment failureSurrogate endpointsTherapeutic radiationAbility of providersVA sitesActual therapyPatientsClinical phenomenaCancerKappa statisticsHealthcare systemMenAmerican Society
2001
The Relative Importance of Anatomic and PSA Factors to Outcomes After Radical Prostatectomy for Prostate Cancer
Vollmer R, Humphrey P. The Relative Importance of Anatomic and PSA Factors to Outcomes After Radical Prostatectomy for Prostate Cancer. American Journal Of Clinical Pathology 2001, 116: 864-870. PMID: 11764075, DOI: 10.1309/7mq7-mwar-4w8a-r75f.Peer-Reviewed Original ResearchConceptsElevated PSA levelsEarly deathPSA levelsRadical prostatectomyProstate cancerPathology observationsGleason grade 5Overall good prognosisTime of prostatectomyPostoperative levelsPSA failureStudy patientsBetter prognosisProgressive tumorsPrognostic categoriesPercentage carcinomaProstatectomySubsequent outcomesLower hazardDeathSurgeryHigher hazardCancerMenPSA
1997
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
Fair W, Cookson M, Stroumbakis N, Cohen D, Aprikian A, Wang Y, Russo P, Soloway S, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg C, Heston W, Reuter V. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997, 49: 46-55. PMID: 9123736, DOI: 10.1016/s0090-4295(97)00169-6.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyMargin-positive rateADT groupPathologic stagingRadical prostatectomyProstatic cancerMonths of ADTControl groupNeoadjuvant androgen deprivation therapyPreoperative androgen deprivation therapyDisease-free survival ratesDisease-free rateMonths of goserelinNeoadjuvant androgen deprivationPSA failure ratesPhase II studySubset of patientsAdditional therapeutic interventionsArea of oncologyDefinitive surgeryDeprivation therapyNeoadjuvant chemotherapyPSA failureBiochemical failureControl patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply